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Edited by Miguel De la RosaAbstract Tom1 (Target of Myb1) is suggested to be involved in
the transport of ubiquitinated proteins, through the interaction of
its GAT (GGA and Tom1) domain with ubiquitin. Here, we dem-
onstrate that the three-helix bundle of Tom1-GAT has two ubiq-
uitin-binding sites recognizing the hydrophobic Ile44 surface of
ubiquitin. The complex crystal structure demonstrates that the
ﬁrst site is a hydrophobic patch on helices a1 and a2. NMR
and biochemical data revealed that the N-terminal half of helix
a3 of Tom1-GAT constitutes the second, stronger binding site.
The double-sided ubiquitin binding enhances the eﬃciency of rec-
ognition of ubiquitinated proteins by Tom1.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Myb1; Ubiquitin recognition1. Introduction
Target of Myb1 (Tom1) has been shown to inhibit the inter-
leukin-1b-induced signaling pathways, which leads to the acti-
vation of transcription factors NF-jB and AP-1 [1]. Tom1
contains an N-terminal Vps27/Hrs/Stam (VHS) domain fol-
lowed by a GAT domain, both of which are also found in Gol-
gi-localizing, c-adaptin ear domain homology, ARF-binding
(GGA) proteins. The GAT domain of Tom1, but not GGAs,
interacts with Toll-interacting protein (Tollip) [2,3]. Tollip is
not only involved in the Toll-like receptor signaling as a nega-
tive regulator [4,5], but also interacts with ubiquitin through its
CUE domain [6]. On the other hand, the GAT domains of
both GGAs and Tom1 were found to interact with ubiquitinAbbreviations: Tom1, Target of Myb1; GGA, Golgi-localizing, c-
adaptin ear domain homology, ARF-binding; GAT, GGA and Tom1;
VHS, Vps27/Hrs/Stam; Tollip, Toll-interacting protein; SPR, surface
plasmon resonance
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doi:10.1016/j.febslet.2005.08.076[2,3,7–9]. These studies have lead to a notion that Tom1 is in-
volved in the intracellular sorting of ubiquitinated proteins as
well as in the signaling pathway, thus serves as an intermediary
between them. Here, we report the crystal structure of the
Tom1-GAT domain in complex with ubiquitin and demon-
strate that a three-helix bundle of Tom1-GAT contains two
ubiquitin-binding surfaces, using a combination of X-ray crys-
tallography, NMR, surface plasmon resonance (SPR) and
pull-down experiments.2. Materials and methods
2.1. Protein puriﬁcation and crystallization
Human Tom1-GAT domain (residues 215–309) was cloned into
pGEX-6P-1 (Amersham) and expressed in Escherichia coli BL21 cells.
The expressed protein was aﬃnity-puriﬁed by glutathione–Sepharose
4B (Amersham), cleavaged by PreScission Protease (Amersham), and
further puriﬁed by gel ﬁltration. Tom1-GAT was dialyzed against a
buﬀer of 1 mM Tris–HCl, pH 8.0, and concentrated to 13 mg ml1.
The mixture of equimolar (1 mM each protein) amounts of Tom1-
GAT and bovine ubiquitin (Sigma) was crystallized using the hang-
ing-drop vapor diﬀusion method. Crystals were obtained using
1.0 M sodium citrate, and 0.1 M cacodylate (pH 6.8) as a reservoir
solution at 20 C. Selenomethionine-substituted Tom1-GAT/ubiquitin
complex was crystallized in almost the same condition as the native
complex.2.2. X-ray data collection and structure determination
Crystals were cryoprotected in the reservoir solution supplemented
with 15% ethylene glycol and frozen in liquid nitrogen. Data were col-
lected at beam lines PF BL-6A and PF AR-NW12, and processed with
HKL2000 [10]. The selenium positions were located and phases were
calculated with SOLVE [11]. Density modiﬁcation and initial model
building was carried out with RESOLVE [12]. Further manual model
building was continued with TURBO-FRODO [13], and CNS [14] was
used for reﬁnement of the model. The ﬁnal reﬁned model consists of
residues 215–307 of GAT and residues 1–76 of ubiquitin. Figures were
drawn with MOLSCRIPT [15], Raster3D [16], POVScript+ [17] and
GRASP [18]. The atomic coordinates have been deposited in the Pro-
tein Data Bank (Accession No. 1WRD).
2.3. Ubiquitin-binding assay of GAT mutants
The pull down experiments and SPR-binding assay were carried out
in the same way as described elsewhere [19]. CD spectra of the GAT
mutants were recorded on a Jasco J-820 spectropolarimeter at 25 C
using a cuvette with 1 mm path length.blished by Elsevier B.V. All rights reserved.
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For chemical shift perturbation experiments, wild type or mutated
(E256N or L285R) Tom1-GAT (141–316 residues) was added to the
0.3 mM [15N]ubiquitin, prepared as described in [19], in 10 mMFig. 1. (A) Crystal structure of Tom1-GAT/ubiquitin complex, and (B) a view
GAT molecule (red), GGA1-GAT (blue) and GGA3-GAT (cyan), in the sa
Table 1
Data collection and reﬁnement statistics
Data collection statistics
Crystal Native SeMet (MAD
Space group F432
Unit cell (A˚) 168.3
(peak)
Wavelength (A˚) 0.9780 0.9791
Resolution (A˚)a 50–1.75 50–3.0
(1.81–1.75) (3.11–3.0)
Total reﬂections 311359 58943
Unique reﬂections 21120 4466
Completeness (%)a 99.5 (99.4) 99.9 (100.0)
Rmerge (%)
a 5.7 (42.1) 12.2 (31.9)
I/r(I)a 20.9 (8.1) 7.4 (6.0)
Reﬁnement statistics
Resolution range (A˚) 40–1.75
No. of reﬂections 20997
No. of non-hydrogen atoms
Protein 1699
Water 291
Rwork (%) 21.1
Rfree (%) 25.6
R.m.s. deviations
Bond length (A˚) 0.011
Bond angle () 1.24
Average B-factors (A˚2)
Tom1-GAT 21.0
ubiquitin 29.6
Water 39.0
aValues in parentheses are for the highest resolution shell.Tris–HCl, pH 7.4. Chemical shift change or line-broadening ob-
served upon addition of 0.3 mM Tom1-GAT were mapped. NMR
spectra were acquired at 30 C on a Bruker Avance 600 MHz
spectrometer.rotated by 90 about the horizontal axis. (C) Superposition of Tom1-
me view as (A).
set)
(edge) (remote1) (remote2)
0.9794 0.9850 0.9740
50–3.0 50–3.0 50–3.0
(3.11–3.0) (3.11–3.0) (3.11–3.0)
59110 59125 59095
4465 4475 4466
99.9 (100.0) 99.9 (100.0) 99.9 (100.0)
11.9 (33.8) 11.6 (36.1) 13.3 (40.8)
7.1 (5.6) 7.0 (5.3) 6.5 (4.8)
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3.1. X-ray crystal structure of the Tom1-GAT/ubiquitin complex
The structure of the Tom1-GAT domain in complex with
ubiquitin was determined by the multiwavelength anomalous
dispersion (MAD) method and reﬁned to a resolution of
1.75 A˚ (Fig. 1A,B and Table 1). The crystal contains one
GAT domain and one ubiquitin per asymmetric unit. The
three-helix bundle structure of Tom1-GAT is superimposed
well with the corresponding three helices of GGA1-GAT (res-
idues 210–299) [20] and GGA3-GAT (residues 218–296) [19]
(root mean square deviation (rmsd) of 1.36 A˚ for Ca atoms)
(Fig. 1C). On the other hand, the structure of ubiquitin in com-
plex with Tom1-GAT is very similar to the previously reported
free ubiquitin structure (rmsd of 0.43 A˚ for Ca atoms of resi-
dues 1–72) [21].
The ubiquitin-binding site of Tom1-GAT is composed of
the C-terminal half of helix a1 and the N-terminal half of he-
lix a2, covering 542 A˚2 of the ubiquitin Ile44 surface (Figs. 2
and 3A). We refer to this ubiquitin-binding site of Tom1-
GAT as Site 1, because it corresponds to ubiquitin-binding
Site 1 of GGA3-GAT [19]. We previously proposed that
the ubiquitin Ile44 surface has three distinct binding pockets,
I, II, and III, for GGA3-GAT [19]. Tom1-GAT Site 1 also
uses these three pockets (Fig. 3A–C). First, Val233 of GAT
helix a1 sticks into pocket I formed by Leu8, Ile44, His68
and Val70. Second, Met237 of GAT helix a1 enters pocket
II formed by Ile44, Ala46, Gly47 and Lys48. Third, Leu253Fig. 2. Sequence alignment and secondary structure of GAT and ubiquit
structure and sequence alignment of GAT (lower panel). Boxes above the
among Tom1, Tom1L1 and GGA3 are shown in red letters. Residues conserve
GGA3 are shown in green and blue letters, respectively. Red asterisks above
Site 1 of Tom1. Black asterisks below the GGA3 sequence indicate GGA3 re
the sequence of ubiquitin. Boxes and arrows above the sequence show a-hel
which interact with Tom1-GAT on Site 1.of GAT helix a2 plugs into pocket III formed by Arg42,
Ile44, Gln49 and Val70. While all these interactions are
hydrophobic, this interface is further stabilized by one salt
bridge between Glu256 of GAT and Arg42 of ubiquitin. In
addition, there are additional interactions at the periphery
of the Ile44 surface (Fig. 3A).
Although the interaction modes are similar between Sites 1
of GGA3 and Tom1, relative orientation between the GAT
domain and ubiquitin are signiﬁcantly diﬀerent between the
two complexes (Fig. 4). In the crystal structure of GGA3-
GAT/ubiquitin, there are two modes of interactions, ‘‘Arg42
upright’’ and ‘‘Arg42 inclined’’, between the two proteins
depending on the orientation of the Arg42 side chain [19]. In
the Tom1-GAT/ubiquitin complex, ubiquitin Arg42 stays
away from Glu252 of Tom1, corresponding to Glu246 of
GGA3, and makes only one salt bridge with Glu256 of
Tom1, corresponding to Glu250 of GGA3 (Fig. 3A). In this re-
spect, the ubiquitin Arg42 side chain of the Tom1-GAT/ubiq-
uitin complex is even more ‘‘upright’’ and helix a2 turns away
about 20 compared to that of ‘‘Arg42-inclined’’ GGA3-GAT/
ubiquitin complex (Fig. 4).
3.2. Dual binding of ubiquitin by Tom1-GAT
Our previous mutational analysis demonstrated that L285R
and D289G mutants of the N-terminal half of Tom1-GAT
helix a3 (opposite to Site 1 and hereafter refer to Site 2) re-
duced the interaction with ubiquitin [2]. To investigate if
ubiquitin indeed binds to Site 1 in solution, we introducedin. (A) Domain organization of Tom1 (upper panel) and secondary
sequences show a-helical regions of Tom1-GAT. Residues conserved
d between Tom1 and Tom1L1 and those conserved between Tom1 and
the Tom1 sequence indicate residues which interact with ubiquitin on
sidues which interact with ubiquitin [19]. (B) Secondary structures and
ical and b-strand regions, respectively. Red asterisks indicate residues
Fig. 3. Ubiquitin-binding Site 1 of Tom1-GAT. (A) Stereo ribbon representation of the interface between Site 1 of Tom1-GAT (red) and
ubiquitin (blue), in the same view as Fig. 1A. Side chains of Tom1-GAT and ubiquitin directly involved in the interactions are shown in ball-
and-stick models with labels. The salt bridge between Glu256 and Arg42 is indicated by a red line. (B) The molecular surface of ubiquitin is
shown with a ribbon drawing of GAT, in the same view as (A). Hydrophobic residues of ubiquitin are colored green. Residues participating in
the interaction are labeled. (C) The molecular surface of GAT is shown with a line drawing of ubiquitin, in the view rotated 180 about the
vertical axis relative to (A).
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bridge interaction with Arg42 of ubiquitin (Fig. 3A). A
pull-down assay using poly- and mono-ubiquitin shows that
both E256N (Site 1) and L285R (Site 2) mutations reduced
the ubiquitin-binding ability signiﬁcantly, albeit some residual
binding (Fig. 5, lanes 3–5). The E256N/L285R double mutant
showed a further decrease in the avidity for ubiquitin (Fig. 5,
lane 6).
We next performed SPR experiments to quantify the ubiq-
uitin binding of the various Tom1-GAT mutants. Mono-
ubiquitin was allowed to bind to the GST-fused GAT which
had been immobilized on a sensor chip. Dissociation con-
stants (Kd) and the maximum ubiquitin-binding capacity,
Rmax, of the interactions were determined and summarized
in Table 2. The Rmax values of mutants were 50–80% of
the wild type suggesting that each single GAT mutation sup-
pressed the binding capacity, although not completely. The
Kd values of Site 2 mutants are signiﬁcantly increased com-
pared to that of wild type, whereas those of Site 1 mutants
are slightly decreased, suggesting the weak interaction at Site
1 and the strong interaction at Site 2. Circular dichroism
spectra of all the mutants, except M237A which showed aslightly decreased helical content, were identical to that of
the wild type, indicating that the global secondary structure
remained intact (Fig. 6).
3.3. Both Sites 1 and 2 of GAT interact with ubiquitin Ile44
surface
On the surface of Tom1-GAT Site 2, Leu285 of helix a3
makes a hydrophobic patch together with Leu269 and Ile272
of helix a2, which is a possible binding site of the hydrophobic
Ile44 surface of ubiquitin. To test this, we made an I44Amutant
of GST-fused ubiquitin and subjected it to a pull-down experi-
ment. The I44A mutation lost the binding aﬃnity to Tom1-
GAT almost completely (Fig. 7, lane 4), which suggests that
Ile44 of ubiquitin is indeed essential for the interaction with
Tom1-GAT at both Sites 1 and 2. Nevertheless, in the crystal
structure, Site 2 of Tom1-GAT is facing another symmetry-re-
lated GAT, which is likely an artifact of the crystal packing.
Although we searched for crystal forms with diﬀerent crystal
packing extensively, our attempts have been unsuccessful so far.
We therefore turned to NMR titration experiments to map
chemical shift perturbations of isotopically labelled ubiquitin
upon binding to Tom1-GAT. The wild-type and the two mu-
Fig. 5. Binding of Tom1-GAT mutants to ubiquitin. Upper panel, a
mixture of polyubiquitin chains and monoubiquitin was pulled down
with GST or GST fused to wild type (WT) or mutant Tom1-GAT
domain and then subjected to immunoblotting with anti-ubiquitin
antibody. Ten percent of the input sample was loaded in the input lane.
Lower panel shows a Coomassie Brilliant Blue (CBB) staining of GST
fusion proteins.
Fig. 4. Comparison of Site 1 interactions of Tom1 and GGA3. The
superposition of the structures of the two GGA3-GAT/ubiquitin
complexes in diﬀerent binding modes [19] onto that of Tom1-GAT/
ubiquitin complex, in the view rotated 45 about the vertical axis
relative to Fig. 1A. The ubiquitin molecules (blue) of the three complex
structures were used for superimposition of the three complex struc-
tures. Tom1-GAT, GGA3-GAT (Arg42-inclined) and GGA3-GAT
(Arg42-upright) molecules are colored red, green and yellow, respec-
tively. Helices a1 and a2 are represented as cylinder models. Helix a2 of
Tom1-GAT slightly bends in the middle. Axes of helices a2 (black lines)
and their relative angles are shown.
Table 2
SPR measurements of Tom1-GAT mutants/ubiquitin interaction
Kd (lM) Rmax
WT 409 ± 13 150 ± 2
Site 1
V233A 278 ± 5 121 ± 1
V233S 236 ± 7 86 ± 1
M237A 241 ± 14 70 ± 1
L253S 234 ± 7 111 ± 1
E256N 282 ± 5 123 ± 1
E256R 245 ± 5 127 ± 1
Site 2
L285R 1555 ± 71 101 ± 3
L285S 2063 ± 151 104 ± 5
D289G 1533 ± 105 130 ± 5
D289R 1840 ± 137 117 ± 5
Sites 1 and 2
E256N/L285R 6117 ± 5260 30 ± 21
Fig. 6. CD measurements of Tom1-GAT mutants. CD spectra of
Tom1-GAT wild type and all the mutants listed in Table 2 were
normalized to the mean residue molar ellipticity.
Fig. 7. Binding of ubiquitin mutants to Tom1-GAT. Upper panel, a
lysate from E. coli cells expressing His6/T7-tagged Tom1-GAT was
pulled down with GST or GST fused wild type (WT) or mutant
ubiquitin (I44A) and subjected to immunoblotting with anti-T7 tag
antibody. One percent of the input sample was loaded in the input
lane. Lower panel, CBB staining of GST fusion proteins.
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Fig. 8. NMR chemical shift perturbation mapping of the Tom1-binding site of ubiquitin. The perturbed residues of ubiquitin upon binding of Tom1-
GAT were mapped onto the ubiquitin structure, viewed in the same direction as Fig. 1A. The chemical shift perturbations are quantiﬁed for each
residue according to the equation ð0:2d2N þ d2HÞ1=2, where dN and dH represent the changes in nitrogen and proton chemical shifts. Perturbed residues
are colored in red with a gradient reﬂecting the strength of the perturbation. Signiﬁcantly perturbed residues (more than 0.2 ppm) are labeled.
Residues whose peaks became undetectable upon binding to ubiquitin are shown in purple and labeled. Residues whose HSQC peaks were not
observed are shown in gray.
5390 M. Akutsu et al. / FEBS Letters 579 (2005) 5385–5391tants, E256N and L285R, of Tom1-GAT all exhibited essen-
tially the same pattern of chemical shift perturbations around
the ubiquitin Ile44 surface (Fig. 8). The Site 1 mutant, E256N,
showed more pronounced perturbations than the Site 2 mu-
tant, L285R, consistent with the SPR measurement indicating
stronger Site 2 binding. Taken together, we conclude that
ubiquitin indeed employs the Ile44 surface to interact with
both Sites 1 and 2, and the Site 2 interaction is the stronger
of the two.3.4. Implication of the Tom1-GAT and ubiquitin interaction
It has been reported that the both Tom1 and Tollip can
interact with ubiquitin even after the formation of a Tom1/
Tollip complex [3]. We have shown that mutations of
Leu285 or Asp289 of Site 2 do not interfere with the Tollip
binding [2], which means Tollip does not need these Site 2 res-
idues for Tom1 interaction, thus implying that Site 1 might be
a possible binding site of Tollip. Because Site 1 binds ubiquitin
rather weakly, Tollip would be able to expel ubiquitin from
Site 1 easily. This leads to a possibility of a quaternary com-
plex of Tom1-GAT, Tollip and two ubiquitin molecules where
the ﬁrst ubiquitin is bound on Site 2 of Tom1-GAT and the
second ubiquitin on the CUE domain of Tollip. This complex
provides a platform for a sequential transfer of ubiquitinated
proteins between Tom1 and Tollip. By these mechanisms,
Tom1 might regulate the fate of internalized ubiquitinated
receptors by delivering them to the lysosomal lumen for degra-
dation via the MVB pathway instead of recycling these recep-
tors to the plasma membrane.
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